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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of mechanical insufﬂator/exsufﬂator (MI-E) and the breath-stacking technique for reducingmorbidity andmortality
and enhancing quality of life in people with amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
B A C K G R O U N D
Description of the condition
Amyotrophic lateral sclerosis (ALS), which is also known as mo-
tor neuron disease (MND), is a progressive, neurodegenerative
condition that causes signiﬁcant disability and shortens life ex-
pectancy. Two to three new cases per 100,000 people occur each
year, with a prevalence of ﬁve to seven affected individuals per
100,000 population (del Aguila 2003; Kiernan 2011). There is no
cure and average life expectancy is two to three years from symp-
tom onset (Alonso 2009). The only available disease-modifying
therapy, riluzole, has a modest effect on the disease course (Paillisse
2005); however, supportive measures delivered via a multidisci-
plinary team approach have been demonstrated to improve out-
comes (Aridegbe 2013). In this regard, management of respiratory
symptoms is an important facet of care for people with ALS.
Non-invasive ventilation (NIV) has the largest impact on survival
and quality of life of any therapeutic intervention for ALS reported
to date (Bourke 2006). A common and distressing symptom faced
by people with ALS with respiratory muscle weakness and bulbar
(laryngeal) dysfunction is the inability to cough well enough to
mobilise and expel secretions from the airway (Lahrmann 2003;
Servera 2003). Inspiratory muscle weakness limits the depth of
the pre-cough inspiration, bulbar weakness impairs glottic closure,
and expiratory muscle weakness reduces intrathoracic expiratory
pressure, all or any of which are associated with ALS and reduce
cough ﬂow and efﬁcacy (Hadjikoutis 1999). In addition, neu-
romuscular bulbar dysfunction impairs swallowing and increases
the risk of aspiration of food or liquid. Peripheral atelectasis sec-
ondary to respiratory muscle weakness creates a susceptibility to
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increased airway and lung secretions. These factors combined may
increase the requirement to cough. Cough effectiveness is subopti-
malwhenpeak coughﬂow (PCF) is less than270L/min (Toussaint
2009). An effective cough protects against respiratory tract infec-
tions, which are the most common cause of hospital admission
in people with respiratory muscle weakness (Bach 1997; Lechtzin
2001; Servera 2003). During chest infections, already impaired
pulmonary function is further compromised by airway mucus ac-
cumulation, fatigue and worsening dysfunction of weak respira-
tory muscles. Secretions that plug the airway can result in partial
or complete collapse of the lung contributing to acute or acute-
on-chronic respiratory failure, which remains the most common
cause of death in ALS (Corcia 2008; Kiernan 2011).
Traditionally, manual chest physiotherapy (MCP) has been used
to assist recovery during chest infections. MCP requires consider-
able time and effort by the person with ALS and a trained thera-
pist. Furthermore, MCP alone is unlikely to be sufﬁcient to clear
airway secretions when the person has advanced respiratory mus-
cle weakness. Hence mechanical aids may be required to enhance
cough.
Description of the intervention
Manual insufﬂator devices (used for the breath-stacking tech-
nique) andmechanical insufﬂator/exsufﬂator (MI-E, coughAssist)
devices, have been used as non-invasive aids to assist cough in
neuromuscular disorders (Mustfa 2003; Tzeng 2000). MI-E was
introduced during the polio epidemic to help people supported
by ’iron lung’ ventilators (Bach 1992; Bach 1993a; Barach 1953;
Barach 1954). Tzeng and Bach developed and followed up use of
a home protocol combining NIV with cough assist techniques in
people with ALS. They concluded that people using the protocol
had signiﬁcantly fewer hospitalisations per year; days hospitalised
reduced from a mean (standard deviation (SD)) of 20.14 ± 41.15
days per year to 1.43 ± 3.71 days per year per person upon the
introduction of MI-E (Tzeng 2000). Further physiological stud-
ies demonstrated that MI-E achieved higher PCF rates than other
methods of cough augmentation (Anderson 2005; Chatwin 2003;
Mustfa 2003; Winck 2004; ). The American Academy of Neurol-
ogy Practice Parameters recommended the use ofMI-Es for people
with neuromuscular respiratory weakness, particularly during an
acute chest infection (Miller 2009). In the absence of a randomised
controlled trial (RCT), however, evidence to support the use of
MI-E was considered weak (level 3). Evidence in favour of the
breath-stacking technique is even weaker. Signiﬁcantly increased
PCFs have been demonstrated in people with neuromuscular dis-
ease, who were able to breath-stack successfully (Armstrong 2009;
Cleary 2013; Kang 2000).
How the intervention might work
MI-E is an electronicmachinewhich simulates cough by delivering
alternate cycles of positive and negative pressure to the airways
through a face mask. It can also be used with a mouthpiece or
tracheostomy. The positive pressure increases inspiratory pressure,
and the negative pressure increases expiratory pressure (Morrow
2013). The machine can generate a pressure of up to +60/-60
cmH2O. The volume of air and PCF exsufﬂated using MI-E are
comparable to those expulsed during normal adult coughing (Bach
1993b).
The breath-stacking technique uses a bag valve mask (BVM, or
self-inﬂating resuscitator) to deliver large breath volumes to the
person with ALS via a suitable interface. The device has a one-
way valve, allowing air ﬂow into the airway to enhance inspira-
tory effort. The lungs are inﬂated as fully as possible by stacking
successive breaths without expiration i.e. holding the successively
inspired air volume against a closed glottis. Once the lungs are
maximally inﬂated, the person releases the compressed air volume
under expiratory muscle force, thus generating a cough with lung
and chest wall recoil. Lechtzin 2006 demonstrated in a prospec-
tive study that supra-maximal lung inﬂation improves lung com-
pliance, possibly by correcting atelectasis (partially collapsed lung
tissue due to reduced air ﬂow). Another study showed that PCF
improved by 50 L/min after treatment with breath-stacking, and
this improvement was sustained for about 30 minutes (Armstrong
2009). Breath-stacking has been shown to improve inspiratory vol-
ume, correct atelectasis, enhance rib cage movement and improve
voice volume (Cleary 2009). However, this is a difﬁcult technique
requiring reasonable respiratory muscle strength and co-ordina-
tion. Furthermore, people with bulbar muscle weakness may ﬁnd
it impossible to retain the volumes of air acquired by stacking, due
to inability to close the glottis. Breath-stacking can be combined
with a chest compression, abdominal thrust, or both, synchronised
with the person’s coughing following maximal insufﬂation (Bach
2004).
Why it is important to do this review
Although the above-mentioned observational studies have con-
ﬁrmed the safety and efﬁcacy of cough augmentation techniques
and there is clinical experience of several decades, the use of these
techniques has not been systematically incorporated into the care
of people with ALS. A systematic review of evidence demonstrat-
ing efﬁcacy and beneﬁt of cough augmentation techniques would
strengthen the case for funding of these interventions for people
with ALS. This review will examine current evidence on the ef-
fects of MI-E and the breath-stacking technique on pulmonary
morbidity, quality of life and survival in people with ALS-related
respiratory failure.
O B J E C T I V E S
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To assess the effects of mechanical insufﬂator/exsufﬂator (MI-E)
and the breath-stacking technique for reducing morbidity and
mortality and enhancing quality of life in people with amyotrophic
lateral sclerosis (ALS)/motor neuron disease (MND).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) and quasi-
RCTs. Quasi-randomised trials are studies that allocate partici-
pants to groups using methods that are partly systematic, for ex-
ample by alternation, use of a case record number, or date of at-
tendance. We will include studies reported as full text, those pub-
lished as abstract only, and unpublished data. There will be no
restrictions as to language.
Types of participants
Wewill include adults of all age groupswith a diagnosis of ALS and
neuromuscular respiratory failure. The participantsmust fulﬁll the
El Escorial criteria for deﬁnite ALS, clinically probable ALS, or
clinically probable laboratory-supported ALS.
Types of interventions
We will include trials comparing:
1. MI-E with other cough augmentation techniques, standard
care or no intervention; and
2. breath-stacking with other cough augmentation techniques,
standard care or no intervention.
We will include trials that incorporate co-interventions (for exam-
ple, non-invasive ventilation (NIV)) provided that the co-inter-
ventions are offered to each group equally.
Types of outcome measures
Primary outcomes
1. Number of chest infections requiring antibiotic treatment
during the follow-up period.
2. Number of hospital admissions for chest infections during
the follow-up period.
Secondary outcomes
1. Change in quality of life (assessed by a validated measure
such as SF36 or sleep apnoea quality of life index) from baseline
to 12 months.
2. Survival at 12 months.
3. Change in impact on the primary carer (assessed by a
validated measure such as the Carer Strain Index) from baseline
to 12 months.
4. Change in peak cough ﬂow (assessed by peak ﬂow meter)
and forced vital capacity (FVC) expressed as percentage
predicted from baseline to 12 months.
5. Adverse events, reported as any adverse events, adverse
events which lead to discontinuation of treatment and serious
adverse events, that is, those which are fatal, life-threatening, or
require prolonged hospitalisation.
Search methods for identification of studies
Electronic searches
We will identify trials from the Cochrane Neuromuscular Disease
Group Specialised Register, which is maintained by the Informa-
tion Specialist for the Group; the Cochrane Central Register of
Controlled Trials (CENTRAL); MEDLINE; and EMBASE. The
draft MEDLINE strategy is in Appendix 1.
We will also conduct a search of the US National Insti-
tutes of Health Clinical Trials Registry, ClinicalTrials.gov (
www.ClinicalTrials.gov) and the World Health Organization
International Clinical Trials Registry Platform (ICTRP) (
apps.who.int/trialsearch/). We will search all databases from their
inception to the present, and we will impose no restriction on
language of publication.
Searching other resources
We will search reference lists of all relevant primary studies and
review articles for additional references. We will search relevant
manufacturers’ websites for trial information.
Data collection and analysis
Selection of studies
Two review authors (MKR and NM) will independently screen
titles and abstracts of all the studies we identify from the search for
inclusion, and code them as ’retrieve’ (eligible or potentially eligi-
ble/unclear) or ’do not retrieve’. We will obtain the full-text study
reports/publications and two review authors (MKR and NM) will
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independently screen the full text and identify studies for inclu-
sion, and identify and record reasons for exclusion of the ineligible
studies. We will resolve any disagreement through discussion or,
if required, we will consult a third person (CJM). We will identify
and exclude duplicates and collate multiple reports of the same
study so that each study rather than each report is the unit of inter-
est in the review. We will record the selection process in sufﬁcient
detail to complete a PRISMA ﬂow diagram and ’Characteristics
of excluded studies’ table.
Data extraction and management
For study characteristics and outcome data we will use a data
extraction form that has been piloted on at least one study in
the review. One review author (MKR and NM) will extract study
characteristics from included studies. We will extract the following
study characteristics.
1. Methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline characteristics, inclusion
criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes speciﬁed and
collected, and time points reported. We will collect data on
attrition, loss to follow-up and the extent of missing data from
each study.
5. Funding for trial, and notable conﬂicts of interest of trial
authors.
6. Notes.
Two review authors (MKR and NM) will independently extract
outcome data from included studies. We will note in the ’Char-
acteristics of included studies’ table if outcome data were not re-
ported in a usable way.Wewill resolve disagreements by consensus
or by involving a third person (CJM). One review author (MKR)
will transfer data into Review Manager (RevMan 2014). Extrac-
tion and input of all outcome data will be veriﬁed by the statisti-
cian (MB). A second review author (CJM) will spot-check study
characteristics for accuracy against the trial report.
When reports require translation, the translator will extract data
directly using a data extraction form, or authors will extract data
from the translation provided.Where possible a review author will
check numerical data in the translation against the study report.
Assessment of risk of bias in included studies
Two review authors (MKR andNM)will independently assess risk
of bias for each study, with disagreements resolved by discussion
or by involving another author (CJM). The criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011) are as follows.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will grade each potential source of bias as high, low or unclear
risk, and provide a quote from the study report together with a
justiﬁcation for our judgement in the ’Risk of bias’ table. Given the
nature of these interventions we envisage blinding of study partic-
ipants (item 3) to be unattainable. We will summarise the ’Risk of
bias’ judgements across different studies for each of the outcomes.
We will consider blinding separately for different key outcomes
where necessary (e.g. for unblinded outcome assessment, risk of
bias for all-cause mortality may be very different than for a par-
ticipant-reported pain scale). Where information on risk of bias
relates to unpublished data or correspondence with a trialist, we
will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as risk ratios (RRs), survival
outcomes as hazard ratios (HRs) and continuous data as mean
difference, or standardised mean difference for results across stud-
ies with outcomes that are conceptually the same but measured
in different ways. We will enter data presented as a scale with a
consistent direction of effect.
We will undertake meta-analyses only where this is meaningful;
that is, if the treatments, participants and the underlying clinical
question are similar enough for pooling to make sense.
Where multiple trial treatment arms are reported in a single trial,
we will include only the eligible arms. If two comparisons (e.g.
treatment A versus placebo and treatment B versus placebo) are
combined in the same meta-analysis, we will halve the control
group to avoid double-counting.
Unit of analysis issues
For cross-over trials, we will include data from the whole follow-
up period. For studies with more than one intervention group, we
will include each group separately in the meta-analysis.
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Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data where possible (for example when a study is available as an
abstract only). Where this is not possible, and the missing data
are thought to introduce serious bias, we will explore the impact
of including such studies in the overall assessment of results by a
sensitivity analysis.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
trials in each analysis. If we identify substantial unexplained het-
erogeneity we will report it and explore possible causes by prespec-
iﬁed subgroup analysis.
We will use the rough guide to interpretation that is outlined in
theCochrane Handbook for Systematic Reviews of Interventions:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity; and
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
We will assess the potential for bias using the ’Risk of bias’ tool
(as noted previously). We will produce a funnel plot to investigate
possible small study biases, bearing in mind its limitations if (as
expected) few trials are identiﬁed.
Data synthesis
We will be mindful of the fact that ALS is a heterogeneous con-
dition; there are at least three sub-types and each sub-type has a
difference prognosis. As stated above, we will ensure that the par-
ticipants fulﬁll the El Escorial criteria for deﬁnite ALS, clinically
probable ALS, or clinically probable laboratory-supported ALS.
If included trials are sufﬁciently similar and combining their data
makes sense clinically, we will pool results in a meta-analysis us-
ing both ﬁxed-effect and random-effects models, and assess their
consistency. Where data cannot be pooled, the results will be de-
scribed in a narrative form. Given the likely small number of trials,
we will describe inconsistencies qualitatively but if data allow will
apply meta-regression methodologies.
If the review includes more than one comparison, which cannot
be included in the same analysis, we will report the results for each
comparison separately.
’Summary of findings’ table
We will create a ’Summary of ﬁndings’ table using the following
outcomes (see Types of outcome measures).
1. Pulmonary morbidity (number of chest infections treated
in hospital and in the community).
2. Change in quality of life.
3. Survival.
4. Change in impact on the primary carer.
5. Change in peak cough ﬂow and FVC.
6. Adverse events.
Two review authors will use the ﬁve GRADE considerations
(study limitations, consistency of effect, imprecision, indirectness
and publication bias) to independently assess the quality of a
body of evidence (studies that contribute data for the prespec-
iﬁed outcomes). They will resolve disagreements by discussion,
involving other review authors if necessary. The review authors
will use methods and recommendations described in Section 8.5
and Chapter 12 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011) using GRADEproGDT software
(GRADEproGDT 2015).We will justify all decisions to down- or
up-grade the quality of studies using footnotes and we will make
comments to aid readers’ understanding of the review where nec-
essary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analysis (depending
on the availability of sufﬁcient reported data).
1. Normal to mildly impaired bulbar function and moderate
to severely impaired bulbar function.
We will use the following outcomes in subgroup analyses.
1. Average number of chest infections requiring antibiotic
therapy per year.
2. Survival.
We will use the formal test for subgroup interactions in Review
Manager (RevMan 2014).
Sensitivity analysis
We plan to carry out the following sensitivity analyses.
1. Repeat the analysis excluding unpublished studies (if there
are any).
2. Repeat the analysis excluding studies at high risk of bias (for
example, quasi-randomised studies, at high risk of selection bias).
3. If there is one or more very large studies, repeat the analysis
excluding them to look at how much they dominate the results.
Reaching conclusions
We will base our conclusions only on ﬁndings from the quantita-
tive or narrative synthesis of included studies for this review. We
will avoid making recommendations for practice and our impli-
cations for research will suggest priorities for future research and
outline the remaining uncertainties in the area.
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A P P E N D I C E S
Appendix 1. MEDLINE (OvidSP) search strategy
DRAFT STRATEGY
Database: Ovid MEDLINE(R) <1946 to November Week 1 2014>
Search Strategy:
--------------------------------------------------------------------------------
1 randomized controlled trial.pt. (399610)
2 controlled clinical trial.pt. (90639)
3 randomized.ab. (294664)
4 placebo.ab. (154739)
5 drug therapy.fs. (1783968)
6 randomly.ab. (206726)
7 trial.ab. (306795)
8 groups.ab. (1313596)
9 or/1-8 (3363515)
10 exp animals/ not humans.sh. (4092437)
11 9 not 10 (2865537)
12 exp Motor Neuron Disease/ (20976)
13 (moto$1 neuron$1 disease$1 or moto neuron$1 disease$1).mp. (6513)
14 amyotrophic lateral sclerosis.mp. (17523)
15 ((Lou Gehrig$1 adj5 syndrome$1) or (Lou Gehrig$1 adj5 disease)).mp. (112)
16 charcot disease.tw. (18)
17 or/12-16 (25416)
18 insufﬂation/ (1607)
19 (insufﬂation or exsufﬂation).mp. (5268)
20 (cough adj1 assist$).tw. (85)
21 (cough adj2 augment$).tw. (37)
22 MI-E.mp. (30)
23 lung volume recruitment.mp. (47)
24 breath stacking.mp. (14)
25 or/18-24 (5407)
26 11 and 17 and 25 (15)
27 remove duplicates from 26 (13)
C O N T R I B U T I O N S O F A U T H O R S
MKR wrote the protocol. NM and CJM critically reviewed the protocol. MB made a substantial contribution as a statistician.
D E C L A R A T I O N S O F I N T E R E S T
MR: none known
MB: none known
NM: none known
CJM is the Chief Investigator on an NIHR Health Technology Assessment (HTA) and Motor Neurone Disease Association (MNDA)-
funded study investigating the role of diaphragmatic pacing in ALS. This study has also received support from Synapse Biomedical in
the form of pacing devices provided at no cost and technical support relating to device implantation and malfunction. CJM is a co-
investigator on an MNDA-funded trial of cough assist devices in MND.
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DA: none known
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